enGene Therapeutics Inc.
ENGN
enGene Therapeutics Inc. is a clinical-stage biotechnology company focused on mainstreaming gene therapy through non-viral delivery of therapeutics to mucosal tissues and other organs. Its lead program, detalimogene voraplasmid (detalimogene), targets non-muscle invasive bladder cancer (NMIBC), particularly in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS), with or without papillary disease. This therapy is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, including a pivotal cohort. enGene Therapeutics Inc. leverages its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables localized delivery of diverse gene cargos such as DNA and various forms of RNA directly to target tissues. Operating in the biotechnology and medical research sector, the company addresses diseases with high unmet clinical needs by developing genetic medicines that penetrate mucosal barriers effectively. Headquartered in Saint-Laurent, Quebec, Canada, enGene Therapeutics Inc. plays a role in advancing innovative treatments for oncology and other challenging indications through its DDX technology.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$127M
▼ -112.7% YoY
Op. Margin
–
ROIC
-39.14%
▼ -13.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$111M
▼ -104.7% YoY
Op. Cash Flow (TTM)
-$105M
▼ -115.3% YoY
Net Debt
-$162M
Net Cash Position
Cash & Equiv.
$194M
Continue Research
Peers
Biotechnology · Pick stocks to compare with ENGN
enGene Therapeutics (ENGN) in three numbers
Questions about enGene Therapeutics
Is enGene Therapeutics a high-quality business?
enGene Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is net debt at -$162M, and its weakest is return on capital at -39.1%. The Quality tab shows every check against its target.
Does enGene Therapeutics (ENGN) pay a dividend?
No. enGene Therapeutics (ENGN) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing ENGN
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.